Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN MICHAEL HUMENIUK

Allopathic & Osteopathic Physicians Dermatology Procedural Dermatology

NPI
1639164528
CMS profile
164457
Location
GREER, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$2,895.44

65 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 65 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN MICHAEL HUMENIUK

NPI 1639164528 · CMS profile ID 164457

Allopathic & Osteopathic Physicians / Dermatology / Procedural Dermatology

GREER, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 65 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1639164528?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN MICHAEL HUMENIUK, NPI 1639164528, CMS profile ID 164457. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 65 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1639164528?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). JOHN MICHAEL HUMENIUK, NPI 1639164528, CMS profile ID 164457. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 65 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1639164528?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
JOHN MICHAEL HUMENIUK, NPI 1639164528, CMS profile ID 164457, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 65 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1639164528?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

65 matching records · $2,895.44 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 65 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 65.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $99.9912/21/2020 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719213719 CMS
Janssen Biotech, Inc. $22.3912/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719213721 CMS
Lilly USA, LLC $16.8512/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728492817 CMS
Novartis Pharmaceuticals Corporation $19.1012/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725818693 CMS
Amgen Inc. $23.4612/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741402043 CMS
AbbVie Inc. $16.4212/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721890657 CMS
AbbVie Inc. $5.1512/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721890653 CMS
UCB, Inc. $29.9412/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 746117563 CMS
Lilly USA, LLC $23.8611/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728499573 CMS
Janssen Biotech, Inc. $13.4211/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719213735 CMS
Janssen Biotech, Inc. $9.2811/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719213725 CMS
AbbVie Inc. $19.2811/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721890649 CMS
AbbVie Inc. $15.6411/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721890645 CMS
VYNE Pharmaceuticals Inc. $15.1711/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753205625 CMS
PFIZER INC. $22.7011/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743513791 CMS
Janssen Biotech, Inc. $22.0510/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719213723 CMS
Novartis Pharmaceuticals Corporation $11.3610/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725818689 CMS
AbbVie Inc. $29.3510/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721890643 CMS
UCB, Inc. $23.8710/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 746097513 CMS
Amgen Inc. $16.5710/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741402041 CMS
Janssen Biotech, Inc. $14.5009/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719213733 CMS
Lilly USA, LLC $23.8509/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728478585 CMS
Janssen Biotech, Inc. $24.5709/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719213715 CMS
AbbVie Inc. $20.2309/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721890639 CMS
Janssen Biotech, Inc. $14.6908/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719213717 CMS
PFIZER INC. $20.4608/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743381363 CMS
Amgen Inc. $25.5708/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741402039 CMS
AbbVie Inc. $1,200.0008/18/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721890635 CMS
GENZYME CORPORATION $18.3308/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744039130 CMS
Janssen Biotech, Inc. $15.0808/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719213731 CMS
AbbVie Inc. $14.0608/11/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721890631 CMS
AbbVie Inc. $18.0008/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721890627 CMS
UCB, Inc. $30.1308/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 746087393 CMS
AbbVie Inc. $16.1807/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721890623 CMS
Lilly USA, LLC $12.7207/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728499571 CMS
Janssen Biotech, Inc. $18.2507/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719213711 CMS
AbbVie Inc. $17.9907/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721890621 CMS
PFIZER INC. $18.9406/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743248697 CMS
AbbVie Inc. $300.0006/29/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721890617 CMS
UCB, Inc. $33.2906/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 746063145 CMS
AbbVie Inc. $14.5606/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721890613 CMS
Novartis Pharmaceuticals Corporation $13.3006/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725818683 CMS
Janssen Biotech, Inc. $29.7606/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719213709 CMS
Amgen Inc. $18.9406/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741402035 CMS
Amgen Inc. $21.0406/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741402037 CMS
Lilly USA, LLC $17.7005/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728499569 CMS
AbbVie Inc. $18.1005/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721890611 CMS
GENZYME CORPORATION $24.2405/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744039017 CMS
Janssen Biotech, Inc. $7.5405/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719213707 CMS
PFIZER INC. $18.0405/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743181131 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $25,604.12 117
PY2020 $2,895.44 65
PY2021 $4,732.54 94
PY2022 $1,979.67 121
PY2023 $2,624.08 110
PY2024 $2,124.43 89
PY2025 $1,626.42 82

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,779.18 1
PY2024 Principal investigator $1,014.39 1
PY2021 Principal investigator $20,911.87 7
PY2020 Principal investigator $203,548.79 150
PY2019 Principal investigator $201,051.33 169

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

169 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $1,569.00 12/17/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514683
Principal investigator 1 Incyte Corporation $1,076.00 12/17/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514685
Principal investigator 1 Incyte Corporation $995.00 12/17/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514687
Principal investigator 1 Incyte Corporation $997.00 12/17/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514689
Principal investigator 1 Incyte Corporation $1,079.00 12/17/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514691
Principal investigator 1 Incyte Corporation $991.00 12/17/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514693
Principal investigator 1 Incyte Corporation $50.00 12/17/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514695
Principal investigator 1 Incyte Corporation $1,569.00 12/17/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514707
Principal investigator 1 Incyte Corporation $1,076.00 12/17/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514709
Principal investigator 1 Incyte Corporation $1,079.00 12/17/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514711
Principal investigator 1 Incyte Corporation $1,079.00 12/17/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514713
Principal investigator 1 Incyte Corporation $1,079.00 12/17/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514715
Principal investigator 1 Incyte Corporation $50.00 12/17/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514717
Principal investigator 1 Incyte Corporation $50.00 12/17/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514719
Principal investigator 1 Incyte Corporation $50.00 12/17/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514721
Principal investigator 1 Incyte Corporation $50.00 12/17/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514723
Principal investigator 1 Incyte Corporation $50.00 12/17/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514725
Principal investigator 1 Incyte Corporation $50.00 12/17/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514727
Principal investigator 1 Incyte Corporation $50.00 12/17/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514729
Principal investigator 1 Incyte Corporation $50.00 12/17/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514731
Principal investigator 1 Incyte Corporation $50.00 12/17/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514733
Principal investigator 1 Incyte Corporation $50.00 12/17/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514735
Principal investigator 1 Incyte Corporation $50.00 11/22/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514561
Principal investigator 1 Incyte Corporation $95.00 11/22/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514563
Principal investigator 1 Incyte Corporation $997.00 11/22/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514565
Principal investigator 1 Incyte Corporation $995.00 11/22/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514567
Principal investigator 1 Incyte Corporation $1,076.00 11/22/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514569
Principal investigator 1 Incyte Corporation $1,569.00 11/22/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514571
Principal investigator 1 Incyte Corporation $1,466.00 11/22/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514573
Principal investigator 1 Incyte Corporation $50.00 11/22/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514615
Principal investigator 1 Incyte Corporation $50.00 11/22/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514617
Principal investigator 1 Incyte Corporation $50.00 11/22/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514619
Principal investigator 1 Incyte Corporation $50.00 11/22/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514621
Principal investigator 1 Incyte Corporation $50.00 11/22/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514623
Principal investigator 1 Incyte Corporation $50.00 11/22/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514625
Principal investigator 1 Incyte Corporation $50.00 11/22/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514627
Principal investigator 1 Incyte Corporation $997.00 11/22/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514629
Principal investigator 1 Incyte Corporation $997.00 11/22/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514631
Principal investigator 1 Incyte Corporation $1,569.00 11/22/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514633
Principal investigator 1 Incyte Corporation $1,569.00 11/22/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514635
Principal investigator 1 Incyte Corporation $1,569.00 11/22/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514637
Principal investigator 1 Incyte Corporation $1,466.00 11/22/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514639
Principal investigator 1 Incyte Corporation $1,466.00 11/22/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514641
Principal investigator 1 Incyte Corporation $1,466.00 11/22/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514643
Principal investigator 1 Incyte Corporation $1,466.00 11/22/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514645
Principal investigator 1 Incyte Corporation $50.00 11/22/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514647
Principal investigator 1 Incyte Corporation $50.00 11/22/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514649
Principal investigator 1 Incyte Corporation $50.00 11/22/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514651
Principal investigator 1 Incyte Corporation $50.00 11/22/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514653
Principal investigator 1 Incyte Corporation $50.00 11/22/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514655
Principal investigator 1 Incyte Corporation $50.00 11/22/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514657
Principal investigator 1 Incyte Corporation $50.00 11/22/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514659
Principal investigator 1 Incyte Corporation $50.00 11/22/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514661
Principal investigator 1 Incyte Corporation $50.00 11/22/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514663
Principal investigator 1 Incyte Corporation $50.00 11/22/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514665
Principal investigator 1 Incyte Corporation $50.00 11/22/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514667
Principal investigator 1 Incyte Corporation $50.00 11/22/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514669
Principal investigator 1 Incyte Corporation $50.00 11/22/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514697
Principal investigator 1 Incyte Corporation $50.00 11/22/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514699
Principal investigator 1 Incyte Corporation $50.00 11/22/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514701
Principal investigator 1 Incyte Corporation $50.00 11/22/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514703
Principal investigator 1 Incyte Corporation $50.00 11/22/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514705
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,193.13 11/13/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 639736769
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,230.63 11/06/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 639736765
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,963.31 11/06/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 639736767
Principal investigator 1 AbbVie, Inc. $75.00 10/28/2019 Non-covered Recipient Entity
Synexus Clinical Research US Inc
M15-997 No dispute reported 06/30/2026 647583909
Principal investigator 1 AbbVie, Inc. $1,616.00 10/21/2019 Non-covered Recipient Entity
Synexus Clinical Research US Inc
M15-997 No dispute reported 06/30/2026 647583911
Principal investigator 1 Incyte Corporation $1,169.00 10/02/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514549
Principal investigator 1 Incyte Corporation $1,502.00 10/02/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514551
Principal investigator 1 Incyte Corporation $1,466.00 10/02/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514553
Principal investigator 1 Incyte Corporation $1,076.00 10/02/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514555
Principal investigator 1 Incyte Corporation $995.00 10/02/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514557
Principal investigator 1 Incyte Corporation $50.00 10/02/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514559
Principal investigator 1 Incyte Corporation $1,169.00 10/02/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514575
Principal investigator 1 Incyte Corporation $1,502.00 10/02/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514577
Principal investigator 1 Incyte Corporation $1,502.00 10/02/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514579
Principal investigator 1 Incyte Corporation $1,466.00 10/02/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514581
Principal investigator 1 Incyte Corporation $1,466.00 10/02/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514583
Principal investigator 1 Incyte Corporation $1,466.00 10/02/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514585
Principal investigator 1 Incyte Corporation $1,466.00 10/02/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514587
Principal investigator 1 Incyte Corporation $995.00 10/02/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514589
Principal investigator 1 Incyte Corporation $995.00 10/02/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514591
Principal investigator 1 Incyte Corporation $50.00 10/02/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514593
Principal investigator 1 Incyte Corporation $50.00 10/02/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514595
Principal investigator 1 Incyte Corporation $50.00 10/02/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514597
Principal investigator 1 Incyte Corporation $50.00 10/02/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514599
Principal investigator 1 Incyte Corporation $50.00 10/02/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514601
Principal investigator 1 Incyte Corporation $50.00 10/02/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514603
Principal investigator 1 Incyte Corporation $50.00 10/02/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514605
Principal investigator 1 Incyte Corporation $50.00 10/02/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514607
Principal investigator 1 Incyte Corporation $50.00 10/02/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514609
Principal investigator 1 Incyte Corporation $50.00 10/02/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514611
Principal investigator 1 Incyte Corporation $50.00 10/02/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514613
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $148.76 09/18/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 639736763
Principal investigator 1 UCB Biosciences Inc. $187.53 09/13/2019 Non-covered Recipient Entity
RADIANT RESEARCH
A MULTICENTER, OPEN-LABEL STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS No dispute reported 06/30/2026 643247405
Principal investigator 1 Incyte Corporation $1,169.00 09/03/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514489
Principal investigator 1 Incyte Corporation $1,502.00 09/03/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514491
Principal investigator 1 Incyte Corporation $1,466.00 09/03/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514493
Principal investigator 1 Incyte Corporation $1,569.00 09/03/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514495
Principal investigator 1 Incyte Corporation $46.00 09/03/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514497
Principal investigator 1 Incyte Corporation $1,076.00 09/03/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514499
Principal investigator 1 Incyte Corporation $1,169.00 09/03/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514523
Principal investigator 1 Incyte Corporation $1,169.00 09/03/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514525
Principal investigator 1 Incyte Corporation $1,502.00 09/03/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514527
Principal investigator 1 Incyte Corporation $1,502.00 09/03/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514529
Principal investigator 1 Incyte Corporation $1,466.00 09/03/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514531
Principal investigator 1 Incyte Corporation $46.00 09/03/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514533
Principal investigator 1 Incyte Corporation $1,076.00 09/03/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514535
Principal investigator 1 Incyte Corporation $1,076.00 09/03/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514537
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,230.63 08/28/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 639736757
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12.50 08/28/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 639736759
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 08/28/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 639736761
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $111.57 08/21/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 639736755
Principal investigator 1 Incyte Corporation $1,169.00 08/05/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514481
Principal investigator 1 Incyte Corporation $1,466.00 08/05/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514483
Principal investigator 1 Incyte Corporation $1,569.00 08/05/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514485
Principal investigator 1 Incyte Corporation $46.00 08/05/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514487
Principal investigator 1 Incyte Corporation $1,169.00 08/05/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514511
Principal investigator 1 Incyte Corporation $1,169.00 08/05/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514513
Principal investigator 1 Incyte Corporation $1,466.00 08/05/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514515
Principal investigator 1 Incyte Corporation $1,466.00 08/05/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514517
Principal investigator 1 Incyte Corporation $1,569.00 08/05/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514519
Principal investigator 1 Incyte Corporation $1,569.00 08/05/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514521
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $260.33 07/31/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 639736749
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $110.00 07/31/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 639736751
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $106.25 07/31/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 639736753
Principal investigator 1 AbbVie, Inc. $1,278.50 07/29/2019 Non-covered Recipient Entity
Synexus Clinical Research US Inc
M15-997 No dispute reported 06/30/2026 647583907
Principal investigator 1 AbbVie, Inc. $75.00 07/26/2019 Non-covered Recipient Entity
Synexus Clinical Research US Inc
M15-997 No dispute reported 06/30/2026 647583905
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $889.33 07/24/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 639736747
Principal investigator 1 UCB SA $187.53 07/18/2019 Non-covered Recipient Entity
RADIANT RESEARCH
A MULTICENTER, OPEN-LABEL STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS No dispute reported 06/30/2026 653520397
Principal investigator 1 Incyte Corporation $1,169.00 07/09/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514501
Principal investigator 1 Incyte Corporation $1,502.00 07/09/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514503
Principal investigator 1 Incyte Corporation $1,466.00 07/09/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514505
Principal investigator 1 Incyte Corporation $1,569.00 07/09/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514507
Principal investigator 1 Incyte Corporation $882.00 07/09/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514509
Principal investigator 1 Incyte Corporation $1,502.00 07/09/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514539
Principal investigator 1 Incyte Corporation $1,466.00 07/09/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514541
Principal investigator 1 Incyte Corporation $1,466.00 07/09/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514543
Principal investigator 1 Incyte Corporation $1,466.00 07/09/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514545
Principal investigator 1 Incyte Corporation $1,466.00 07/09/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666514547
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $669.42 06/19/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 639736745
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $110.00 06/05/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 639736741
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $158.75 06/05/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 639736743
Principal investigator 1 AbbVie, Inc. $1,616.00 05/29/2019 Non-covered Recipient Entity
Synexus Clinical Research US Inc
M15-997 No dispute reported 06/30/2026 647583903
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $110.00 05/22/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 639736737
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $118.75 05/22/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 639736739
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,863.65 05/15/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 639736735
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,099.18 04/17/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 639736733
Principal investigator 1 UCB SA $373.43 04/15/2019 Non-covered Recipient Entity
RADIANT RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY WITH A 24-WEEK ACTIVE-CONTROLLED INITIAL TREATMENT PERIOD FOLLOWED BY A 32-WEEK, DOSE-BLIND MAINTENANCE TREATMENT PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS No dispute reported 06/30/2026 653520381
Principal investigator 1 AbbVie, Inc. $2,709.50 03/28/2019 Non-covered Recipient Entity
Synexus Clinical Research US Inc
M15-997 No dispute reported 06/30/2026 647583913
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,783.69 03/27/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 639736731
Principal investigator 1 Eli Lilly and Company $111.45 03/26/2019 Covered Recipient Teaching Hospital
KALISPELL REGIONAL MEDICAL CENTER
A MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LY2439821 TO ETANERCEPT AND PLACEBO IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 654286019
Principal investigator 1 UCB SA $7,438.40 03/14/2019 Non-covered Recipient Entity
RADIANT RESEARCH INC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, STUDY FOLLOWED BY A DOSE-BLIND PERIOD AND OPEN LABEL FOLLOW-UP TO EVALUATE THE EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS No dispute reported 06/30/2026 653521029
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $110.00 03/13/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 639736727
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $118.75 03/13/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 639736729
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $48,099.15 03/12/2019 Non-covered Recipient Entity
Clinical Research Advantage, Incorporated
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with an Induction Period Followed by a Randomized Maintenance Period to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to No dispute reported 06/30/2026 639757749
Principal investigator 1 Eli Lilly and Company $4,463.72 03/05/2019 Non-covered Recipient Entity
RADIANT RESEARCH INC
A MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LY2439821 TO ETANERCEPT AND PLACEBO IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 654292439
Principal investigator 1 PFIZER INC. $1,482.00 02/28/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCHUS INC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 COADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO 18 YEARS OF AGE WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 671619209
Principal investigator 1 PFIZER INC. $590.00 02/26/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCHUS INC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 COADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO 18 YEARS OF AGE WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 671619211
Principal investigator 1 PFIZER INC. $225.00 02/25/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCHUS INC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 COADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO 18 YEARS OF AGE WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 671621061
Principal investigator 1 PFIZER INC. $61.62 02/25/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCHUS INC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 COADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO 18 YEARS OF AGE WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 671621063
Principal investigator 1 PFIZER INC. $42.38 02/25/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCHUS INC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 COADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO 18 YEARS OF AGE WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 671621123
Principal investigator 1 PFIZER INC. $49.95 02/25/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCHUS INC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 COADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO 18 YEARS OF AGE WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 671621125
Principal investigator 1 PFIZER INC. $70.00 02/22/2019 Non-covered Recipient Entity
Synexus
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 COADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO 18 YEARS OF AGE WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 671641941
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $110.00 02/04/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 639736775
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $118.75 02/04/2019 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 639736777
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $110.00 01/03/2019 Non-covered Recipient Entity
RADIANT RESEARCH INC
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 639736771
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.75 01/03/2019 Non-covered Recipient Entity
RADIANT RESEARCH INC
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 639736773
Principal investigator 1 Novartis Pharmaceuticals Corporation $14,010.04 01/01/2019 Non-covered Recipient Entity
RADIANT RESEARCH
A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO DETERMINE THE EFFICACY AND SAFETY OF ORAL ZPL389A 3 MG 10 MG 30 MG AND 50 MG CAPSULES ADMINISTERED FOR 16 WEEKS IN SUBJECTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 640724577